Merck & Co., Inc. (NYSE:MRK – Get Free Report) declared a quarterly dividend on Tuesday, November 17th. Shareholders of record on Tuesday, December 15th will be paid a dividend of $0.88 per share on Friday, January 8th. This represents a $3.52 annualized dividend and a yield of 2.5%. The ex-dividend date of this dividend is Tuesday, December 15th. This is a 3.5% increase from Merck & Co., Inc.’s previous quarterly dividend of $0.85.
Merck & Co., Inc. has increased its dividend payment by an average of 0.1% per year over the last three years and has raised its dividend every year for the last 14 years. Merck & Co., Inc. has a payout ratio of 35.0% meaning its dividend is sufficiently covered by earnings. Equities analysts expect Merck & Co., Inc. to earn $9.08 per share next year, which means the company should continue to be able to cover its $3.40 annual dividend with an expected future payout ratio of 37.4%.
Merck & Co., Inc. Trading Down 1.0%
Shares of Merck & Co., Inc. stock opened at $143.01 on Wednesday. Merck & Co., Inc. has a fifty-two week low of $92.11 and a fifty-two week high of $156.92. The firm has a market cap of $352.56 billion, a PE ratio of 147.43, a P/E/G ratio of 6.62 and a beta of 0.13. The business’s fifty day moving average is $145.93 and its two-hundred day moving average is $128.97. The company has a quick ratio of 1.14, a current ratio of 1.35 and a debt-to-equity ratio of 1.11.
Merck & Co., Inc. (NYSE:MRK – Get Free Report) last announced its quarterly earnings data on Thursday, October 29th. The company reported $2.49 EPS for the quarter, beating analysts’ consensus estimates of $2.09 by $0.40. The business had revenue of $18.09 billion during the quarter, compared to the consensus estimate of $17.33 billion. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 3.64%. The business’s revenue for the quarter was up 4.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.58 earnings per share. Analysts anticipate that Merck & Co., Inc. will post 2.82 earnings per share for the current year.
Insiders Place Their Bets
In other Merck & Co., Inc. news, EVP Richard Deluca sold 58,185 shares of the company’s stock in a transaction that occurred on Thursday, November 12th. The stock was sold at an average price of $148.01, for a total value of $8,611,961.85. Following the completion of the sale, the executive vice president directly owned 112,955 shares in the company, valued at $16,718,469.55. This represents a 34.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.17% of the stock is owned by company insiders.
Institutional Trading of Merck & Co., Inc.
Large investors have recently added to or reduced their stakes in the business. Zacks Investment Management raised its position in shares of Merck & Co., Inc. by 1.6% in the 3rd quarter. Zacks Investment Management now owns 1,105,163 shares of the company’s stock worth $160,591,000 after acquiring an additional 17,519 shares in the last quarter. iSAM Funds UK Ltd acquired a new stake in Merck & Co., Inc. in the 3rd quarter valued at $450,000. Integrated Wealth Concepts LLC grew its holdings in shares of Merck & Co., Inc. by 12.7% during the third quarter. Integrated Wealth Concepts LLC now owns 144,351 shares of the company’s stock valued at $20,976,000 after buying an additional 16,283 shares during the last quarter. Groupama Asset Managment increased its holdings in Merck & Co., Inc. by 3.1% during the 3rd quarter. Groupama Asset Managment now owns 1,096,545 shares of the company’s stock worth $159,334,000 after purchasing an additional 32,885 shares in the last quarter. Finally, EWA LLC grew its holdings in Merck & Co., Inc. by 19.0% during the third quarter. EWA LLC now owns 5,239 shares of the company’s stock worth $761,000 after buying an additional 836 shares in the last quarter. 76.07% of the stock is currently owned by institutional investors.
About Merck & Co., Inc.
Merck & Co., Inc. is a global pharmaceutical company that develops and markets prescription medicines, vaccines, biologic therapies and animal-health products. The company’s research and commercial activities span areas including oncology, infectious diseases, vaccines, cardiovascular disease and immunology. Its products include the cancer medicine Keytruda and the Gardasil vaccine. Founded in the United States in 1891, Merck & Co. became an independent company in 1917. It is headquartered in Rahway, New Jersey, and operates internationally.
Recommended Stories
- Five stocks we like better than Merck & Co., Inc.
- AMD Bets $8.2B on Physical AI: Could Robotics Be Its Next Growth Frontier?
- 3 Stocks Flashing Buy Signals With Historical Win Rates Above 85% After the Sell-Off
- Disney Has the Magic Touch: Dividend Growth and Buybacks Could Fuel a Breakout
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
